CA3177940A1 — Optimized nucleotide sequences encoding sars-cov-2 antigens
Assigned to Translate Bio Inc · Expires 2021-11-11 · 5y expired
What this patent protects
The present invention relates to optimized nucleotide sequence encoding SARS-CoV-2 antigens. These sequences are particularly suitable for use in vaccine compositions for the treatment or prevention of infections caused by a ?-coronaviruses, including COVID-19 infections, in a hu…
USPTO Abstract
The present invention relates to optimized nucleotide sequence encoding SARS-CoV-2 antigens. These sequences are particularly suitable for use in vaccine compositions for the treatment or prevention of infections caused by a ?-coronaviruses, including COVID-19 infections, in a human or animal subject in need of such treatment.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.